US 12,325,870 B2
Solubilized apyrases, methods and use
Agostino Cirillo, Basel (CH); Hilmar Ebersbach, Wallisellen (CH); Boerje Haraldsson, Basel (CH); Thomas Huber, Allschwil (CH); Guido Junge, Basel (CH); Regina Link, Münchenstein (CH); Max Warncke, Basel (CH); and Chao Zou, Allschwil (CH)
Assigned to NOVARTIS AG, Basel (CH)
Appl. No. 17/261,533
Filed by NOVARTIS AG, Basel (CH)
PCT Filed Jul. 17, 2019, PCT No. PCT/IB2019/056117
§ 371(c)(1), (2) Date Jan. 19, 2021,
PCT Pub. No. WO2020/016804, PCT Pub. Date Jan. 23, 2020.
Claims priority of application No. 18184269 (EP), filed on Jul. 18, 2018.
Prior Publication US 2022/0356455 A1, Nov. 10, 2022
Int. Cl. C12N 9/14 (2006.01); A61K 38/46 (2006.01); A61K 45/06 (2006.01); A61K 38/00 (2006.01)
CPC C12N 9/14 (2013.01) [A61K 38/465 (2013.01); A61K 45/06 (2013.01); A61K 38/00 (2013.01); C12Y 306/01005 (2013.01)] 8 Claims
 
1. A solubilized human apyrase comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 58, SEQ ID NO: 74, and SEQ ID NO: 229.